190 Utilizing a peptide-based approach to target and evaluate novel biomarker Neu5Gc Sialyl Lewis A in cancer
Main Authors: | Indu Venugopal, Shelby Knoche, Michael J McGuire, Kathlynn C Brown |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
839 TALLTM (Targeted Antigen Loaded Liposomes) immunotherapy exploits recall immunity to form an excellent co-therapy option for immune checkpoint inhibitors
by: Amanda G Powell, et al.
Published: (2023-11-01) -
Selectin Ligands Sialyl-Lewis a and Sialyl-Lewis x in Gastrointestinal Cancers
by: Marco Trinchera, et al.
Published: (2017-02-01) -
Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin
by: Curtis A. Allred, et al.
Published: (2023-01-01) -
At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody
by: Yu, C, et al.
Published: (2016) -
Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?
by: Silvia Pietrobono, et al.
Published: (2021-04-01)